To provide insight into polyaspartic acid nephroprotection and differences in aminoglycoside renal toxicity between two rat strains, the single-dose pharmacokinetics of tobramycin was examined in the presence and absence of polyaspartic acid. Following a single subcutaneous 6.5-mg/kg dose of tobramycin alone, higher aminoglycoside concentrations were measured in Sprague-Dawley rats than in Fischer rats (P < 0.05). Simultaneous administration of polyaspartic acid (50 mg/kg) and tobramycin did not alter the concentrations of tobramycin in serum. The amount of tobramycin in renal tissue and the amount recovered in urine over a 24-h period were greater in both rat strains when tobramycin and polyaspartic acid were given concomitantly. Rats from each strain were randomly assigned to treatment groups in either part 1 or 2 of the experiment. Part 1 addressed serum pharmacokinetics and consisted of 24 rats of each strain that received a single 6.5-mg/kg subcutaneous dose of tobramycin dissolved in sterile water for injection (sterile tobramycin sulfate; kindly donated by Eli Lilly & Co., Indianapolis, Ind.). A low dose of tobramycin was selected to avoid any complicating effect of Ag-induced renal dysfunction on the pharmacokinetics. An additional 24 rats of each strain received the same dose of tobramycin plus 50 mg of PAA (poly-L-aspartic acid, Na salt; molecular weight, 9,600-13,000; Sigma Chemical Co., St. Louis, Mo.) per kg dissolved in sterile water for injection. The PAA was injected subcutaneously at a site distant from the tobramycin immediately after the tobramycin injection. Serum was collected from three rats of each strain and each treatment group at 0, 15, 30, 45, 60, 120, 180, and 240